ICML 2019 | Providing a PLATFORM: first results for liso-cel plus durvalumab in R/R B-cell NHL
Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the first results of the PLATFORM trial (NCT03310619). She discusses the safety of lisocabtagene maraleucel given with durvalumab to patients with relapsed/refractory aggressive B-cell non-Hodgkin lympoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
Get great new content delivered to your inboxSign up